Clinical trials with anti-angiogenic agents in hematological malignancies

Journal of Angiogenesis Research

Volumn 2, Issue 1, 2010, Pages

  Medinger, Michael ^a   Mross, Klaus ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICALINS; ANTINEOPLASTIC AGENT; AZACITIDINE; BEVACIZUMAB; BORTEZOMIB; CEDIRANIB; CYTARABINE; CYTOTOXIC AGENT; DEXAMETHASONE; IDARUBICIN; LENALIDOMIDE; MITOXANTRONE; PRS 050; SEMAXANIB; SORAFENIB; SUNITINIB; THALIDOMIDE; UNCLASSIFIED DRUG; VATALANIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MEGAKARYOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANOREXIA; ANTIANGIOGENIC THERAPY; ASTHENIA; BLEEDING; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LETHARGY; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MANTLE CELL LYMPHOMA; METASTASIS; MONOTHERAPY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; MYELOPROLIFERATIVE NEOPLASM; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SOLID TUMOR; T CELL LEUKEMIA; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT REFUSAL; TREATMENT RESPONSE;

EID: 77954600750     PISSN: None     EISSN: 20402384     Source Type: Journal    
DOI: 10.1186/2040-2384-2-10     Document Type: Review

References (105)

1. Angiogenesis in cancer, vascular, rheumatoid, and other disease. J Folkman, Nat Med 1995 1 27 31 10.1038/nm0195-27 7584949
2. Tumor angiogenesis: therapeutic implications. J Folkman, N Engl J Med 1971 285 1182 1186 4938153
3. Impaired recruitment of bone-marrow derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. D Lyden K Hattori S Dias C Costa P Blaikie L Butros A Chadburn B Heissig W Marks L Witte Y Wu D Hicklin ZP Zhu NR Hackett RG Crystal MAS Moore KA Hajjar K Manova R Benezra S Rafii, Nat Med 2001 7 1194 1201 10.1038/nm1101-1194 11689883
4. The biology of VEGF and its receptors. N Ferrara HP Gerber J LeCouter, Nat Med 2003 9 669 676 10.1038/nm0603-669 12778165
5. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. H Gille J Kowalski B Li J LeCouter B Moffat TF Zioncheck N Pelletier N Ferrara, J Biol Chem 2001 276 3222 3230 10.1074/jbc.M002016200 11058584
6. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. K Hattori S Dias B Heissig NR Hackett D Lyden M Tateno DJ Hicklin Z Zhu L Witte RG Crystal MA Moore S Rafii, J Exp Med 2001 193 1005 1014 10.1084/jem.193.9.1005 11342585
7. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. WT Bellamy L Richter Y Frutiger TM Grogan, Cancer Res 1999 59 728 733 9973224
8. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. M Gill S Dias K Hattori ML Rivera D Hicklin L Witte L Girardi R Yurt H Himel S Rafii, Circ Res 2001 88 167 174 11157668
9. Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor. I Casella T Feccia C Chelucci P Samoggia G Castelli R Guerriero I Parolini E Petrucci E Pelosi O Morsilli M Gabbianelli U Testa C Peschle, Blood 2003 101 1316 1323 10.1182/blood-2002-07- 2184 12406876
10. The delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. G Thurston I Noguera-Troise GD Yancopoulos, Nat Rev Cancer 2007 7 327 331 10.1038/nrc2130 17457300
11. Delta-like 4/Notch signaling and its therapeutic implications. M Yan GD Plowman, Clin Cancer Res 2007 13 7243 7246 10.1158/1078-0432.CCR-07-1393 18094402
12. Hypoxia-mediated activation of Dll4-Notch-Hey2 signaling in endothelial progenitor cells and adoption of arterial cell fate. H Diez A Fischer A Winkler CJ Hu AK Hatzopoulos G Breier M Gessler, Exp Cell Res 2007 313 1 9 10.1016/j.yexcr.2006.09.009 17045587
13. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. I Noguera-Troise C Daly NJ Papadopoulos S Coetzee P Boland NW Gale HC Lin GD Yancopoulos G Thurston, Nature 2006 444 1032 1037 10.1038/nature05355 17183313
14. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. J Ridgway G Zhang Y Wu S Stawicki WC Liang Y Chanthery J Kowalski RJ Watts C Callahan I Kasman M Singh M Chien C Tan JA Hongo F de Sauvage G Plowman M Yan, Nature 2006 444 1083 1087 10.1038/nature05313 17183323
15. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. JL Li RC Sainson W Shi R Leek LS Harrington M Preusser S Biswas H Turley E Heikamp JA Hainfellner AL Harris, Cancer Res 2007 67 11244 11253 10.1158/0008-5472.CAN-07-0969 18056450
16. The role of angiogenesis in the biology and therapy of myelodysplastic syndromes. A Aguayo, Curr Hematol Rep 2004 3 184 191 15087066
17. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status. M Medinger R Skoda A Gratwohl A Theocharides A Buser D Heim S Dirnhofer A Tichelli A Tzankov, Br J Haematol 2009 146 150 157 10.1111/j.1365-2141.2009.07726.x 19466975
18. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. T Padrá S Ruiz R Bieker H Bürger M Steins J Kienast T Büchner WE Berdel RM Mesters, Blood 2000 95 2637 2644 10753845
19. Angiogenesis in myelodysplastic syndromes. G Pruneri F Bertolini D Soligo N Carboni A Cortelezzi PF Ferrucci R Buffa G Lambertenghi-Deliliers F Pezzella, Br J Cancer 1999 81 1398 1401 10.1038/sj.bjc.6693515 10604739
20. Angiogenesis in nodal B cell lymphomas: a high throughput study. A Tzankov S Heiss S Ebner W Sterlacci G Schaefer F Augustin M Fiegl S Dirnhofer, J Clin Pathol 2007 60 476 482 10.1136/jcp.2006.038661 16790692
21. Bone marrow angiogenesis and progression in multiple myeloma. A Vacca D Ribatti L Roncali G Ranieri G Serio F Silvestris F Dammacco, Br J Haematol 1994 87 503 508 10.1111/j.1365-2141.1994.tb08304.x 7527645
22. Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival. S Loges G Heil M Bruweleit V Schoder M Butzal U Fischer UM Gehling G Schuch DK Hossfeld W Fiedler, J Clin Oncol 2005 23 1109 1117 10.1200/JCO.2005.05.058 15718307
23. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase2 secretion parallel progression of human multiple myeloma. A Vacca D Ribatti M Presta M Minischetti M Iurlaro R Ria A Albini F Bussolino F Dammacco, Blood 1999 93 30643073
24. Numerous growth factors, cytokines, and chemokines are secreted by human CD34(+) cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. M Majka A Janowska-Wieczorek J Ratajczak K Ehrenman Z Pietrzkowski MA Kowalska AM Gewirtz SG Emerson MZ Ratajczak, Blood 2001 97 3075 3085 10.1182/blood.V97.10.3075 11342433
25. Vascular endothelial growth factor is a secreted angiogenic mitogen. DW Leung G Cachianes WJ Kuang DV Goeddel N Ferrara, Science 1989 246 1306 1309 10.1126/science.2479986 2479986
26. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. W Fiedler U Graeven S Ergün S Verago N Kilic M Stockschläder DK Hossfeld, Blood 1997 89 1870 1875 9058706
27. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. S Dias K Hattori Z Zhu B Heissig M Choy W Lane, J Clin Invest 2000 106 511 521 10.1172/JCI8978 10953026
28. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. A Aguayo E Estey H Kantarjian T Mansouri C Gidel M Keating, Blood 1999 94 3717 3721 10572084
29. The Notch signaling pathway: transcriptional regulation at Notch target genes. T Borggrefe F Oswald, Cell Mol Life Sci 2009 66 1631 1646 10.1007/s00018-009-8668-7 19165418
30. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. AP Weng AA Ferrando W Lee JP Morris LB Silverman C Sanchez-Irizarry SC Blacklow AT Look JC Aster, Science 2004 306 269 271 10.1126/science.1102160 15472075
31. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. F Jundt I Anagnostopoulos R Förster S Mathas H Stein B Dörken, Blood 2002 99 3398 3403 10.1182/blood.V99.9.3398 11964309
32. Aberrant expression of Notch1 interferes with the B-lymphoid phenotype of neoplastic B cells in classical Hodgkin lymphoma. F Jundt O Acikgöz SH Kwon R Schwarzer I Anagnostopoulos B Wiesner S Mathas M Hummel H Stein HM Reichardt B Dörken, Leukemia 2008 22 1587 1594 10.1038/leu.2008.101 18449208
33. Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia. R Hubmann JD Schwarzmeier M Shehata M Hilgarth M Duechler M Dettke R Berger, Blood 2002 99 3742 3747 10.1182/blood.V99.10.3742 11986231
34. Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2. M Duechler M Shehata JD Schwarzmeier A Hoelbl M Hilgarth R Hubmann, Leukemia 2005 19 260 267 10.1038/sj.leu.2403592 15565166
35. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. E Rosati R Sabatini G Rampino A Tabilio M Di Ianni K Fettucciari A Bartoli S Coaccioli I Screpanti P Marconi, Blood 2009 113 856 865 10.1182/blood-2008-02-139725 18796623
36. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Y Nefedova P Cheng M Alsina WS Dalton DI Gabrilovich, Blood 2004 103 3503 3510 10.1182/blood-2003-07-2340 14670925
37. Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. F Jundt KS Pröbsting I Anagnostopoulos G Muehlinghaus M Chatterjee S Mathas RC Bargou R Manz H Stein B Dörken, Blood 2004 103 3511 3515 10.1182/blood-2003-07-2254 14726396
38. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. A Vacca F Dammacco PG Richardson KC Anderson, Cancer Res 2006 66 184 191 10.1158/0008-5472.CAN-05-1195 16397231
39. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. O Sezer K Niemoller J Eucker C Jakob O Kaufmann I Zavrski M Dietel K Possinger, Ann Hematol 2000 79 574 577 10.1007/ s002770000236 11100749
40. Prognostic value of bone marrow angiogenesis in multiple myeloma. SV Rajkumar T Leong PC Roche R Fonseca A Dispenzieri MQ Lacy JA Lust TE Witzig RA Kyle MA Gertz PR Greipp, Clin Cancer Res 2000 6 3111 3116 10955791
41. Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. NC Munshi C Wilson, Semin Oncol 2001 28 565 569 10.1016/S0093-7754(01)90025-9 11740810
42. Expression of VEGF and its receptors by myeloma cells. S Kumar TE Witzig M Timm J Haug L Wellik R Fonseca PR Greipp SV Rajkumar, Leukemia 2003 17 2025 2031 10.1038/sj.leu.2403084 14513053
43. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. K Podar YT Tai FE Davies S Lentzsch M Sattler T Hideshima BK Lin D Gupta Y Shima D Chauhan C Mitsiades N Raje P Richardson KC Anderson, Blood 2001 98 428 435 10.1182/blood.V98.2.428 11435313
44. The pathophysiological role of VEGF in hematological malignancies: Therapeutic implications. K Podar KC Anderson, Blood 2005 105 138395 10.1182/blood-2004-07-2909 (Pubitemid 40223651)
45. A review of angiogenesis and anti-angiogenic therapy in hematologic malignancies. SV Rajkumar RA Mesa A Tefferi, J Hematother Stem Cell Res 2002 11 33 47 10.1089/152581602753448522 11847002
46. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesisinhibitory activity with disease progression. S Kumar TE Witzig M Timm J Haug L Wellik TK Kimlinger PR Greipp SV Rajkumar, Blood 2004 104 1159 1165 10.1182/blood-2003-11-3811 15130943
47. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. AR Perez-Atayde SE Sallan U Tedrow S Connors E Allred J Folkman, Am J Pathol 1997 150 815 821 9060819
48. Clinical importance of serum vascular endothelial and basic fibroblast growth factors in children with acute lymphoblastic leukemia. S Yetgin I Yenicesu M Cetin M Tuncer, Leuk Lymphoma 2001 42 83 88 10.3109/10428190109097679 11699225
49. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. D Hanahan J Folkman, Cell 1996 86 353 364 10.1016/S0092-8674(00) 80108-7 8756718
50. Angiogenesis and antiangiogenic therapy in hematologic malignancies. X Dong ZC Han R Yang, Crit Rev Oncol/Hematol 2007 62 105 118 10.1016/j.critrevonc. 2006.11.006 (Pubitemid 46584811)
51. Dysregulated angiogenesis in B-chronic lymphocytic leukemia: morphologic, immunohistochemical, and flow cytometric evidence. JL Frater NE Kay CL Goolsby SE Crawford GW Dewald LC Peterson, Diagn Pathol 2008 3 16 10.1186/1746-1596-3-16 18423023
52. Vascular density in childhood acute lymphoblastic leukaemia correlates to biological factors and outcome. U Norén-Nyström M Heyman P Frisk I Golovleva C Sundström A Porwit G Roos A Bergh E Forestier, Br J Haematol 2009 146 521 350 10.1111/j.1365-2141.2009.07796.x 19594745
53. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. A Aguayo HM Kantarjian EH Estey FJ Giles S Verstovsek T Manshouri, Cancer 2002 95 1923 1930 10.1002/cncr.10900 12404286
54. Changes in MR bone marrow angiogenesis on day 7 after induction chemotherapy can predict outcome of acute myeloid leukemia. HA Hou T Ting-Fang Shih CY Liu BB Chen JL Tang M Yao SY Huang WC Chou CY Hsu HF Tien, Haematologica 2010 20220062
55. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. LG Lundberg R Lerner P Sundelin R Rogers J Folkman J Palmblad, Am J Pathol 2000 157 15 19 10880370
56. Increased expression of vascular endothelial growth factor (VEGF) in bone marrow of patients with myeloproliferative disorders (MPD). T Wrobel G Mazur P Surowiak D Wolowiec M Jelen K Kuliczkowsky, Pathol Oncol Res 2003 9 170 173 10.1007/BF03033732 14530810 (Pubitemid 37429496)
57. VEGF expression correlates with microvessel density in Philadelphia chromosome-negative chronic myeloproliferative disorders. U Gianelli C Vener PR Raviele F Savi F Somalvico R Calori A Iurlo F Radaelli E Fermo P Bucciarelli S Bori G Coggi GL Deliliers, Am J Clin Pathol 2007 128 966 973 10.1309/FP0N3LC8MBJUFFA6 18024322
58. Chronic idiopathic myelofibrosis: independent prognostic importance of bone marrow microvascular density evaluated by CD105 (endoglin) immunostaining. M Ponzoni DG Savage AJ Ferreri G Pruneri G Viale P Servida F Bertolini A Orazi, Mod Pathol 2004 17 1513 1520 10.1038/modpathol.3800224 15272276
59. A gain-of-function mutation of JAK2 in myeloproliferative isorders. R Kralovics F Passamonti AS Buser SS Teo R Tiedt JR Passweg A Tichelli M Cazzola RC Skoda, N Engl J Med 2005 352 1779 1790 10.1056/NEJMoa051113 15858187
60. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. R Kralovics SS Teo S Li A Theocharides AS Buser A Tichelli RC Skoda, Blood 2006 108 1377 1380 10.1182/blood-2005-11-009605 16675710
61. Evaluation of circulating endothelial cells, VEGF and VEGFR2 serum levels in patients with chronic myeloproliferative diseases. A Alonci A Allegra G Bellomo G Penna A D'Angelo E Quartarone C Musolino, Hematol Oncol 2008 26 235 239 10.1002/hon.865 18504767
62. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. H Hurwitz L Fehrenbacher W Novotny T Cartwright J Hainsworth W Heim J Berlin A Baron S Griffing E Holmgren N Ferrara G Fyfe B Rogers R Ross F Kabbinavar, N Engl J Med 2004 350 2335 2342 10.1056/NEJMoa032691 15175435
63. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. A Sandler R Gray MC Perry J Brahmer JH Schiller A Dowlati R Lilenbaum DH Johnson, N Engl J Med 2006 355 2542 2550 10.1056/NEJMoa061884 17167137 (Pubitemid 44917502)
64. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. K Miller M Wang J Gralow M Dickler M Cobleigh EA Perez T Shenkier D Cella NE Davidson, N Engl J Med 2007 357 2666 2676 10.1056/NEJMoa072113 18160686
65. Sorafenib in advanced clear-cell renal-cell carcinoma. B Escudier T Eisen WM Stadler C Szczylik S Oudard M Siebels S Negrier C Chevreau E Solska AA Desai F Rolland T Demkow TE Hutson M Gore S Freeman B Schwartz M Shan R Simantov RM Bukowski TARGET Study Group, N Engl J Med 2007 356 125 134 10.1056/NEJMoa060655 17215530
66. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. RJ Motzer TE Hutson P Tomczak MD Michaelson RM Bukowski O Rixe S Oudard S Negrier C Szczylik ST Kim I Chen PW Bycott CM Baum RA Figlin, N Engl J Med 2007 356 115 124 10.1056/NEJMoa065044 17215529
67. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. LG Presta H Chen SJ O'Connor V Chisholm YG Meng L Krummen M Winkler N Ferrara, Cancer Res 1997 57 4593 4599 9377574
68. Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity. L Zahiragic C Schliemann R Bieker NH Thoennissen K Burow C Kramer M Zühlsdorf WE Berdel RM Mesters, Leukemia 2007 21 1310 1312 10.1038/sj.leu.2404632 17330095
69. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d- arabinofuranosylcytosine, mitoxantrone, and bevacizumab. JE Karp I Gojo R Pili CD Gocke J Greer C Guo D Qian L Morris M Tidwell H Chen J Zwiebel, Clin Cancer Res 2004 10 3577 3585 10.1158/1078-0432.CCR-03-0627 15173063
70. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. W Fiedler R Mesters H Tinnefeld S Loges P Staib U Duhrsen M Flasshove OG Ottmann W Jung F Cavalli R Kuse J Thomalla H Serve AM O'Farrell M Jacobs NM Brega P Scigalla DK Hossfeld WE Berdel, Blood 2003 102 2763 2767 10.1182/blood-2002-10-2998 12843001
71. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. RM Mesters T Padrá R Bieker M Steins M Kreuter M Göner S Kelsey P Scigalla W Fiedler T Büchner WE Berdel, Blood 2001 98 241 243 10.1182/blood.V98.1.241 11418488
72. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. FJ Giles AT Stopeck LR Silverman JE Lancet MA Cooper AL Hannah JM Cherrington AM O'Farrell HA Yuen SG Louie W Hong JE Cortes S Verstovsek M Albitar SM O'Brien HM Kantarjian JE Karp, Blood 2003 102 795 801 10.1182/blood-2002-10-3023 12649163
73. PTK787/ZK 22 a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. J Drevs R Müller-Driver C Wittig S Fuxius N Esser H Hugenschmidt MA Konerding PR Allegrini J Wood J Hennig C Unger D Marmé Cancer Res 2584 62 4015 4022
74. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumors. K Mross J Drevs M Müller M Medinger D Marmé J Hennig B Morgan D Lebwohl E Masson YY Ho C Günther D Laurent C Unger, Eur J Cancer 2005 41 1291 1299 10.1016/j.ejca.2005.03.005 15939265
75. PTK787/ZK 22 a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. JM Wood G Bold E Buchdunger R Cozens S Ferrari J Frei F Hofmann J Mestan H Mett T O'Reilly E Persohn J Rösel C Schnell D Stover A Theuer H Towbin F Wenger K Woods-Cook A Menrad G Siemeister M Schirner KH Thierauch MR Schneider J Drevs G Martiny-Baron F Totzke, Cancer Res 2584 60 2178 2189
76. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. B Lin K Podar D Gupta YT Tai S Li E Weller T Hideshima S Lentzsch F Davies C Li E Weisberg RL Schlossman PG Richardson JD Griffin J Wood NC Munshi KC Anderson, Cancer Res 2002 62 5019 5026 12208756
77. Phase 1 study of PTK787/ZK 22 a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. GJ Roboz FJ Giles AF List JE Cortes R Carlin M Kowalski S Bilic E Masson M Rosamilia MW Schuster D Laurent EJ Feldman, Leukemia 2584 20 952 957 10.1038/sj.leu.2404213
78. Additive effect of PTK787/ZK 22 a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia. N Barbarroja LA Torres MJ Luque RM Carretero A Valverde-Estepa LM Lopez-Sanchez A Rodriguez-Ariza F Velasco A Torres C Lápez-Pedrera, Exp Hematol 2584 37 679 691 10.1016/j.exphem.2009.03.001
79. PTK787/ZK 22 a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia. FJ Giles AF List M Carroll JE Cortes J Valickas BL Chen E Masson C Jacques D Laurent M Albitar EJ Feldman GJ Roboz, Leuk Res 2584 31 891 897 10.1016/j.leukres.2006.12.001
80. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. SR Wedge J Kendrew LF Hennequin PJ Valentine ST Barry SR Brave NR Smith NH James M Dukes JO Curwen R Chester JA Jackson SJ Boffey LL Kilburn S Barnett GH Richmond PF Wadsworth M Walker AL Bigley ST Taylor L Cooper S Beck JM Jürgensmeier DJ Ogilvie, Cancer Res 2005 65 4389 4400 10.1158/0008-5472. CAN-04-4409 15899831
81. Phase I clinical study of AZD an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Drevs P Siegert M Medinger K Mross R Strecker U Zirrgiebel J Harder H Blum J Robertson JM Jürgensmeier TA Puchalski H Young O Saunders C Unger, J Clin Oncol 2171 20 3045 3054
82. An open-label, phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia. W Fiedler R Mesters M Heuser G Ehninger WE Berdel U Zirrgiebel JD Robertson TA Puchalski B Collins JM Jürgensmeier H Serve, Leuk Res 2010 34 196 202 10.1016/j.leukres.2009.07.020 19674789
83. Antitumor activity of thalidomide in refractory multiple myeloma. S Singhal J Mehta R Desikan D Ayers P Roberson P Eddlemon N Munshi E Anaissie C Wilson M Dhodapkar J Zeddis B Barlogie, N Engl J Med 1999 341 1565 1571 10.1056/NEJM199911183412102 10564685
84. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. B Barlogie R Desikan P Eddlemon T Spencer J Zeldis N Munshi A Badros M Zangari E Anaissie J Epstein J Shaughnessy D Ayers D Spoon G Tricot, Blood 2001 98 492 494 10.1182/blood.V98.2.492 11435324
85. Thalidomide-effect on T cell subsets as a possible mechanism of action. B Moncada ML Baranda R Gonzlez-Amaro R Urbina CE Loredo, Int J Lepr Other Mycobact Dis 1985 53 201 205 3874920
86. Thalidomide is an inhibitor of angiogenesis. RJ D'Amato MS Loughnan E Flynn J Folkman, Proc Natl Acad Sci USA 1994 91 4082 4085 10.1073/pnas.91.9.4082 7513432
87. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. D Gupta SP Treon Y Shima T Hideshima K Podar YT Tai B Lin S Lentzsch FE Davies D Chauhan RL Schlossman P Richardson P Ralph L Wu F Payvandi G Muller DI Stirling KC Anderson, Leukemia 2001 15 1950 1961 11753617
88. Properties of thalidomide and its analogues: implications for anticancer therapy. SK Teo, AAPS J 2005 7 14 19 10.1208/aapsj070103 16146335
89. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. K Dredge JB Marriott CD Macdonald HW Man R Chen GW Muller D Stirling AG Dalgleish, Br J Cancer 2002 87 1166 1172 10.1038/sj.bjc.6600607 12402158
90. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. SV Rajkumar E Blood D Vesole R Fonseca PR Greipp, J Clin Oncol 2006 24 431 436 10.1200/JCO.2005.03. 0221 16365178
91. Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia. DA Thomas E Estey FJ Giles S Faderl J Cortes M Keating, Br J Haematol 2003 123 436 441 10.1046/j.1365-2141.2003.04639.x 14617002
92. Efficacy and safety of thalidomide in patients with acute myeloid leukemia. MB Steins T Padrá R Bieker S Ruiz M Kropff J Kienast T Kessler T Buechner WE Berdel RM Mesters, Blood 2002 99 834 839 10.1182/blood.V99.3.834 11806984
93. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia. A Raza M Mehdi M Mumtaz F Ali S Lascher N Galili, Cancer 2008 113 1596 1604 10.1002/cncr.23789 18720364
94. Thalidomide therapy for myelofibrosis with myeloid metaplasia. DA Thomas FJ Giles M Albitar JE Cortes S Verstovsek S Faderl SM O'Brien G Garcia-Manero MJ Keating S Pierce J Zeldis HM Kantarjian, Cancer 2006 106 1974 1984 10.1002/cncr.21827 16583431 (Pubitemid 43673213)
95. Mechanism of action of lenalidomide in hematological malignancies. V Kotla S Goel S Nischal C Heuck K Vivek B Das A Verma, J Hematol Oncol 2009 2 36 10.1186/1756-8722-2-36 19674465
96. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. M Dimopoulos A Spencer M Attal HM Prince JL Harousseau A Dmoszynska J San Miguel A Hellmann T Facon R Foa A Corso Z Masliak M Olesnyckyj Z Yu J Patin JB Zeldis RD Knight, N Engl J Med 2007 357 2123 2132 10.1056/NEJMoa070594 18032762 (Pubitemid 350146107)
97. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. DM Weber C Chen R Niesvizky M Wang A Belch EA Stadtmauer D Siegel I Borrello SV Rajkumar AA Chanan-Khan S Lonial Z Yu J Patin M Olesnyckyj JB Zeldis RD Knight, N Engl J Med 2007 357 2133 2142 10.1056/NEJMoa070596 18032763 (Pubitemid 350146108)
98. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. A Tefferi J Cortes S Verstovsek RA Mesa D Thomas TL Lasho WJ Hogan MR Litzow JB Allred D Jones C Byrne JB Zeldis RP Ketterling RF McClure F Giles HM Kantarjian, Blood 2006 108 1158 1164 10.1182/blood-2006-02-004572 16609064 (Pubitemid 44232010)
99. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. A Quints-Cardama HM Kantarjian T Manshouri D Thomas J Cortes F Ravandi G Garcia-Manero A Ferrajoli C Bueso-Ramos S Verstovsek, J Clin Oncol 2009 27 4760 4766 10.1200/JCO.2009.22.6548 19720904
100. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. JB Sunwoo Z Chen G Dong N Yeh C Crowl Bancroft E Sausville J Adams P Elliott C Van Waes, Clin Cancer Res 2001 7 1419 1428 11350913
101. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. AM Roccaro T Hideshima N Raje S Kumar K Ishitsuka H Yasui N Shiraishi D Ribatti B Nico A Vacca F Dammacco PG Richardson KC Anderson, Cancer Research 2006 66 184 191 10.1158/0008-5472.CAN-05-1195 16397231
102. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. RC Kane AT Farrell R Sridhara R Pazdur, Clinical Cancer Research 2006 12 2955 2960 10.1158/1078-0432.CCR-06-0170 16707588
103. Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial. MV Mateos PG Richardson R Schlag NK Khuageva MA Dimopoulos O Shpilberg M Kropff I Spicka MT Petrucci A Palumbo OS Samoilova A Dmoszynska KM Abdulkadyrov R Schots B Jiang DL Esseltine K Liu A Cakana H van de Velde JF San Miguel, J Clin Oncol 2010 28 2259 2266 10.1200/JCO.2009.26.0638 20368561
104. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. PG Richardson E Weller S Lonial AJ Jakubowiak S Jagannath NS Raje DE Avigan W Xie IM Ghobrial RL Schlossman A Mazumder NC Munshi DH Vesole R Joyce JL Kaufman D Doss DL Warren LE Lunde S Kaster C Delaney T Hideshima CS Mitsiades R Knight DL Esseltine KC Anderson, Blood 2010
105. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. EC Attar DJ De Angelo JG Supko F D'Amato D Zahrieh A Sirulnik M Wadleigh KK Ballen S McAfee KB Miller J Levine I Galinsky EG Trehu D Schenkein D Neuberg RM Stone PC Amrein, Clin Cancer Res 2008 14 1446 1454 10.1158/1078-0432.CCR-07-4626 18316568